Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,232 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,676 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06302699 | Detecting Minimal Residual Diseases (MRD) and Monitoring Clonal Evolution Using Ultrasensitive Chromosomal Aberrations Detection (UCAD) in Multiple Myeloma | unknown | — | 80 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT06301321 | The Evaluation and Comparison of BCR-ABL p210 mRNA Transcripts (%IS Unit) Results Between Dr. PCR™ BCR-ABL1 Major IS Detection Kit (Optolane) and QXDx™ BCR-ABL %IS Kit (Bio-Rad) in Chronic Myeloid Leukemia Patients(BCR-ABL1) | unknown | — | 80 |
| Siriraj HospitalOTHER |
| 1 |
| Mar 8, 2024 |
| clinicaltrials |
| NCT03580109 | Spa Therapy for Upper or Lower Limb Lymphoedema(THERMOEDEME) | unknown | N/A | 160 | Association Francaise pour la Recherche ThermaleOTHER | 1 | Mar 6, 2024 | clinicaltrials |
| NCT05066607 | Isatuximab Plus Pomalidomide and Dexamethasone Association for Patients With AL Amyloidosis Not in VGPR or Better After Any Previous Therapy(IsAMYP) | unknown | Phase 2 | 46 | Intergroupe Francophone du MyelomeNETWORK | 1 | Mar 6, 2024 | clinicaltrials |
| NCT05370547 | Chidamide Bridging for CAR-T Therapy | unknown | Phase 1 / Phase 2 | 120 | Chinese PLA General HospitalOTHER | 1 | Mar 6, 2024 | clinicaltrials |
| NCT05697913 | Efficacy of Response-adapted Treatment in Patients With Multiple Myeloma Candidates for Bone Marrow Transplantation | unknown | N/A | 66 | Hospital Galdakao-UsansoloOTHER_GOV | 0 | Mar 6, 2024 | clinicaltrials |
| NCT06242249 | Anti-BCMA CAR-NK Therapy in Relapsed or Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 10 | Shahid Beheshti University of Medical SciencesOTHER | 1 | Mar 6, 2024 | clinicaltrials |
| NCT06296121 | A Study of the Efficacy and Safety of Monotherapy With BCD-264 and Darzalex in Subjects With Relapsed and Refractory Multiple Myeloma(DARVIVA) | unknown | Phase 3 | 252 | BiocadINDUSTRY | 1 | Mar 6, 2024 | clinicaltrials |
| NCT06224452 | Is Ibrutinib-related Atrial Fibrillation Dose Dependent | unknown | — | 18,000 | University Hospital, CaenOTHER | 1 | Mar 5, 2024 | clinicaltrials |
| NCT06293586 | Comparison Between Peribulbar And Sub-tenon Blocks on Oculocardiac Reflex (OCR) During Pediatric Strabismus Surgery | unknown | N/A | 140 | Cairo UniversityOTHER | 1 | Mar 5, 2024 | clinicaltrials |
| NCT06290817 | Orelabrutinib Combined With R-CDOP for DLBCL Patients With High-risk of CNS Relapse Defined by CNS-IPI | unknown | Phase 2 | 62 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Mar 4, 2024 | clinicaltrials |
| NCT03428373 | Rivaroxaban or Aspirin As Thromboprophylaxis in Multiple Myeloma(RithMM) | unknown | Phase 2 / Phase 3 | 57 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 1 | Feb 29, 2024 | clinicaltrials |
| NCT06285136 | Safety and Efficacy of Venetoclax Combination With Decitabine(DEC3-VEN) in the Treatment of AML in the Adult | unknown | Phase 2 / Phase 3 | 40 | The Second Affiliated Hospital of Kunming Medical UniversityOTHER | 1 | Feb 29, 2024 | clinicaltrials |
| NCT06279585 | Physical Therapy in Patients Undergoing Allo-HSCT With cGVHD | unknown | N/A | 108 | University of SevilleOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT03576378 | BrEPEM-LH-22017 for Older Patients With Untreated Hodgkin Lymphoma (HL) | unknown | Phase 1 / Phase 2 | 41 | Grupo Español de Linfomas y Transplante Autólogo de Médula ÓseaOTHER | 1 | Feb 26, 2024 | clinicaltrials |
| NCT04378647 | BREntuximab Vedotin in SEcond LIne Therapy BEfore Transplant(BRESELIBET) | unknown | Phase 2 | 150 | Grupo Español de Linfomas y Transplante Autólogo de Médula ÓseaOTHER | 1 | Feb 26, 2024 | clinicaltrials |
| NCT06277011 | Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research | unknown | Early Phase 1 | 18 | Anhui Provincial HospitalOTHER_GOV | 1 | Feb 26, 2024 | clinicaltrials |
| NCT02192619 | National Acute Promyelocytic Leukemia (APL) Observational Study NAPOLEON-Registry of the German AML Intergroup | unknown | — | 500 | Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbHOTHER | 1 | Feb 23, 2024 | clinicaltrials |
| NCT05346198 | Evaluate CART-BCMA in Patients With Relapsed and/or Refractory Multiple Myeloma | unknown | Phase 1 | 15 | Shanghai Simnova Biotechnology Co.,Ltd.INDUSTRY | 1 | Feb 23, 2024 | clinicaltrials |
| NCT06206902 | F01 in the Treatment of Relapsed/Refractory Non-hodgkin's Lymphoma | unknown | Phase 1 | 55 | Shanghai Simnova Biotechnology Co.,Ltd.INDUSTRY | 1 | Feb 23, 2024 | clinicaltrials |
| NCT05865678 | Musculoskeletal Health in Adult Haematological Cancer Survivors(SKETCh) | unknown | — | 650 | The Christie NHS Foundation TrustOTHER | 1 | Feb 21, 2024 | clinicaltrials |
| NCT01754402 | Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma | unknown | Phase 1 / Phase 2 | 56 | Cristina GasparettoOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT03650933 | A Study Comparing the Efficacy and Safety of G-CHOP Versus R-CHOP in Untreated Diffuse Large B-cell Lymphoma Patients | unknown | Phase 3 | 360 | Nanjing Yoko Biomedical Co., Ltd.INDUSTRY | 1 | Feb 20, 2024 | clinicaltrials |
| NCT06066255 | PROPHYLAXIS OF GVH IN ELDERLY PATIENTS RECEIVING HAPLOIDENTICAL ALLOGENIC HEMATOPOIETIC STEM CELL TRASNPLANTATION USE OF A LOW DOSE ANTI-LYMPHOCYTIC SERUM(CASPER) | unknown | Phase 2 | 27 | Institut Paoli-CalmettesOTHER | 0 | Feb 20, 2024 | clinicaltrials |
| NCT06186167 | Amyloidosis Incidence in High-Risk Cardiac Device Patients | unknown | — | 100 | Midwest Heart & Vascular SpecialistsOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT06238245 | Combination of ATG-based Conditioning Regimen and PTCy for GVHD Prevention in Allo-HSCT After PD-1 Blockade | unknown | Phase 2 | 22 | Beijing 302 HospitalOTHER | 0 | Feb 20, 2024 | clinicaltrials |
| NCT06148220 | A Study of the Clinical Application of [18F]RCCB6 and [68Ga]Ga-NOTA-RCCB6 PET/CT Imaging in the Diagnosis of CD70-expressing Multiple Tumors | unknown | N/A | 20 | Huashan HospitalOTHER | 1 | Feb 16, 2024 | clinicaltrials |
| NCT05284825 | A Phase II Trial of Intermediate Radiation Dose For Lymphoma | unknown | N/A | 27 | Sunnybrook Health Sciences CentreOTHER | 1 | Feb 15, 2024 | clinicaltrials |
| NCT06258096 | LI-TASTE Study: Light for Taste(LI-TASTE) | unknown | N/A | 52 | Academic Centre for Dentistry in AmsterdamOTHER | 0 | Feb 14, 2024 | clinicaltrials |
| NCT05840107 | Study of FasT CAR-T GC012F Injection NDMM Patients | unknown | Early Phase 1 | 18 | Shanghai Changzheng HospitalOTHER | 1 | Feb 13, 2024 | clinicaltrials |
| NCT05904522 | Histopathological Changes in Mycosis Fungoides | unknown | N/A | 10 | Bezmialem Vakif UniversityOTHER | 1 | Feb 13, 2024 | clinicaltrials |
| NCT06255639 | Biomechanical and Metabolic Assessment Pre and Post Vertebroplasty in Multiple Myeloma Patients With Vertebral Collapse | unknown | — | 20 | Centro di Riferimento Oncologico - AvianoOTHER | 1 | Feb 13, 2024 | clinicaltrials |
| NCT06255847 | Clinical Study of Reduced-dose Pomalidomide and Cyclophosphamide Combined With Dexamethasone in the Treatment of Patients With Debilitating RRMM | unknown | Phase 2 | 43 | Shanxi Bethune HospitalOTHER | 1 | Feb 13, 2024 | clinicaltrials |
| NCT03599960 | Combination Chemotherapy in Patients With Newly Diagnosed BPDCN(LpDessai) | unknown | Phase 2 | 26 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Feb 8, 2024 | clinicaltrials |
| NCT05875428 | Mitoxantrone Hydrochloride Liposome Injection in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | unknown | Phase 2 | 104 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Feb 8, 2024 | clinicaltrials |
| NCT04582487 | Advancing Chemical and Genomic Strategies for Relapsed/Refractory T-ALL and ETP-ALL | unknown | N/A | 32 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT04731974 | Acute Concussion and Melatonin | unknown | Phase 2 | 254 | Children's National Research InstituteOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT05234684 | A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell Lymphoma(BELIEVE-01) | unknown | Phase 3 | 150 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 1 | Feb 7, 2024 | clinicaltrials |
| NCT06246006 | Functional Characterization of Thrombopoietin/cMPL Receptor Mutations in Myeloproliferative Neoplasia(MPL - NPM) | unknown | — | 30 | Centre Hospitalier Universitaire de NīmesOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT06238336 | Clinical Study of CAR-T Technology for the Treatment of Relapsed Refractory Malignant Haematological Tumours | unknown | Phase 2 / Phase 3 | 30 | Shanxi Bethune HospitalOTHER | 1 | Feb 2, 2024 | clinicaltrials |
| NCT04358393 | A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS | unknown | Phase 1 / Phase 2 | 69 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Feb 1, 2024 | clinicaltrials |
| NCT05478993 | Selinexor, Pomalidomide, and Dexamethasone For Multiple Myeloma With CNS Involvement(SPODUMENE) | unknown | Phase 2 | 21 | Peking University People's HospitalOTHER | 1 | Jan 31, 2024 | clinicaltrials |
| NCT06233890 | The Analysis of Fatigue on Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukaemia(TIRE) | unknown | — | 50 | Imperial College Healthcare NHS TrustOTHER | 1 | Jan 31, 2024 | clinicaltrials |
| NCT04983810 | A Study to Investigate Fadraciclib (CYC065), in Subjects With Advanced Solid Tumors and Lymphoma | unknown | Phase 1 / Phase 2 | 330 | Cyclacel Pharmaceuticals, Inc.INDUSTRY | 3 | Jan 25, 2024 | clinicaltrials |
| NCT06223646 | A Study of KQ-2003 CAR-T Cell Therapy for Patients With Relapsed or Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 29 | Novatim Immune Therapeutics (Zhejiang) Co., Ltd.INDUSTRY | 1 | Jan 25, 2024 | clinicaltrials |
| NCT06224842 | Clinical Study of Mitoxantrone Liposome and Azacitidine in the Treatment of R/R AITL | unknown | Phase 1 / Phase 2 | 30 | Huijing WuOTHER | 1 | Jan 25, 2024 | clinicaltrials |
| NCT05150405 | A Phase Ia Clinical Study of QLF31907 Injection in Patients With Advanced Malignant Tumors | unknown | Phase 1 | 54 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 23, 2024 | clinicaltrials |
| NCT05186012 | APG-1252 Monotherapy or in Combination With Other Therapeutic Agent in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma | unknown | Phase 1 / Phase 2 | 51 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Jan 23, 2024 | clinicaltrials |
| NCT06218771 | A Study of TQB3454 Tablets in Patients With Blood Tumors | unknown | Phase 1 / Phase 2 | 80 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jan 23, 2024 | clinicaltrials |
Data updated 22 days agoSource updated Mar 12, 2024source: clinicaltrials